BioMarin Pharmaceutical
$58.44Change from previous close: −2.60%Absolute change: −$1.56
Valuation
Data as of October 2, 2026
Valuation multiples
- Market cap
- $11.31B
- Enterprise value
- $14.64B
- P/E (trailing 12 months)
- 157.9
- Forward P/E
- 8.83
- PEG
- 0.35
- Price/book
- 1.79
- Price/sales
- 3.32
- EV/EBITDA
- 22.7
- EV/revenue
- 4.30
Profitability and growth
- Gross margin
- 51.0%
- Operating margin
- 21.2%
- Net margin
- 2.1%
- ROE
- 1.2%
- ROA
- 3.3%
- Revenue growth (year over year)
- 19.9%
- Earnings growth (year over year)
- -81.3%
Financial health
- Total cash
- $874M
- Total debt
- $4.2B
- Debt/equity
- 0.66
- Current ratio
- 2.39
- Quick ratio
- 1.16
Dividends
- Payout ratio
- 0.0%
Analysts and estimates
- Average price target
- $91.62
- Median price target
- $90.00
- High price target
- $124.00
- Low price target
- $60.00
- Analysts with a price target
- 26
- Consensus
- Buy
- Forward EPS
- $6.62
- EPS estimate, current year
- $4.94
Shares and trading
- Beta
- 0.24
- Average volume
- 1.95M
- Shares outstanding
- 193.57M
- Float
- 192.63M
- Institutional ownership
- 103.5%
- Insider ownership
- 0.3%
- Short interest (% of float)
- 5.2%
- Short ratio (days)
- 5.62